Folate, Methylation, MTHFR and Homocysteine: What the Markers Signal

Few topics in functional medicine generate as much interest, or as much confusion, as methylation and the MTHFR gene. Patients arrive with genetic reports describing themselves as poor methylators, lists of supplements designed to bypass their variants and a sense that their genes explain their fatigue, anxiety or miscarriages. The underlying biochemistry is real and important. The clinical claims built on it often are not. Practitioners need to understand both well enough to explain the difference.

One carbon metabolism in brief

One carbon metabolism is a network of reactions that transfers single carbon units between molecules. 2 interconnected cycles are central.

The folate cycle converts dietary folate into several active forms. One of these, 5 methyltetrahydrofolate, is produced by the enzyme methylenetetrahydrofolate reductase, MTHFR. It donates its methyl group to homocysteine, converting it to methionine, in a reaction that requires vitamin B12.

The methionine cycle converts methionine to S adenosylmethionine, SAMe, the body’s main methyl donor. SAMe provides methyl groups for the methylation of DNA, proteins, neurotransmitters and many other molecules, becoming homocysteine again in the process.

Homocysteine has 2 fates. It can be remethylated to methionine, using folate and B12, or converted through the transsulfuration pathway to cysteine, using vitamin B6. When any of these steps is impaired, homocysteine accumulates.

The same network is essential for DNA synthesis, which is why folate and B12 deficiency both cause megaloblastic anaemia, and for neural tube development in early pregnancy, which is why folic acid prevents neural tube defects.

What causes raised homocysteine

The most useful clinical point is that raised homocysteine is often a signal of a treatable deficiency, particularly of B12 or folate, or of kidney impairment. Those should be looked for first.

The MTHFR variants

The MTHFR gene has 2 common variants. C677T produces an enzyme with reduced activity, especially when folate is scarce. People with 2 copies, homozygous, have roughly a third of normal enzyme activity; the proportion of people homozygous varies greatly between populations, commonly around 1 in 10 and higher in some groups. A second variant, A1298C, has a smaller effect.

The consequences are more modest than many reports suggest. People homozygous for C677T tend to have somewhat higher homocysteine levels, but mainly when folate intake is low. With adequate folate intake, including in countries with folic acid fortification of flour, the difference is small. Many homozygous people have entirely normal homocysteine.

Severe MTHFR deficiency, caused by rare mutations that almost eliminate enzyme activity, is a different condition, usually presenting in childhood with very high homocysteine and neurological problems.

What professional bodies recommend

The American College of Medical Genetics and Genomics has recommended against testing for MTHFR variants in the evaluation of thrombophilia or recurrent pregnancy loss, and against testing at risk family members, concluding that the variants are common, weakly associated with outcomes and that knowing them does not change management. Obstetric bodies have made similar recommendations. Where homocysteine is relevant, measuring homocysteine itself is more informative than genotyping.

Homocysteine and disease

Raised homocysteine is associated in observational studies with cardiovascular disease, stroke, venous thrombosis, cognitive decline and some pregnancy complications. This led to the hypothesis that lowering homocysteine would reduce these conditions.

Large randomised trials tested the hypothesis. B vitamin supplementation reliably lowered homocysteine, but in trials such as HOPE 2 and NORVIT it did not reduce heart attacks or overall cardiovascular events in people with vascular disease. Some trials and meta analyses suggested a modest reduction in stroke, and a large trial in China, where folic acid fortification is absent and folate status is lower, found that adding folic acid to an antihypertensive reduced first strokes. The benefits of lowering homocysteine may therefore depend on baseline folate status and on the outcome being considered.

The lesson is similar to that of other nutrient trials: homocysteine is a useful marker of deficiency and risk, but lowering it in people who are not deficient has not delivered the broad benefits once hoped for.

Folic acid, methylfolate and the claims about them

Folic acid is the synthetic form of folate used in supplements and fortification. It requires conversion in the body, including by MTHFR, to active forms. Some practitioners argue that people with MTHFR variants cannot use folic acid and should take 5 methyltetrahydrofolate, often called methylfolate, instead.

The evidence supports a more measured view. People with MTHFR variants do respond to folic acid, which lowers their homocysteine and, in pregnancy, protects against neural tube defects; the major prevention trials and fortification programmes included people with these variants. Methylfolate is a reasonable alternative, and some people may prefer it, but there is no strong evidence that it is necessary for people with common variants. High doses of either form can mask the anaemia of B12 deficiency while neurological damage progresses, which is why B12 status should be known before high dose folate is used.

Using the markers well

1. Measure homocysteine when it will inform management, such as in suspected B12 or folate deficiency, unexplained thrombosis under specialist care or certain metabolic presentations.
2. If it is raised, look for causes: B12, folate and B6 status, kidney and thyroid function, medicines and lifestyle.
3. Treat deficiencies with appropriate doses of the relevant vitamins, correcting B12 before or alongside folate.
4. Advise folic acid before conception for all who may become pregnant, regardless of genotype.
5. Avoid routine MTHFR genotyping, and help patients who have been tested understand what their result does and does not mean.
6. Be cautious with high dose methylation protocols built on genotype alone.

Talking to a patient with an MTHFR report

Consider an illustrative patient: a 33 year old woman who has had 2 miscarriages and brings a consumer genetic report stating she is homozygous for MTHFR C677T. She has been told she cannot absorb folic acid and has stopped her prenatal vitamin.

The practitioner explains that this variant is common, that its effect is small when folate intake is adequate, that professional bodies do not consider it a cause of recurrent pregnancy loss, and that folic acid remains effective and important before and during pregnancy. Her homocysteine, B12 and folate are checked and are normal. She restarts a prenatal supplement, choosing one containing methylfolate because she feels more comfortable with it, and is referred for appropriate assessment of recurrent miscarriage. Her anxiety about her genes eases, and the most important protective step, folate before conception, is back in place.

Biochemistry and perspective

One carbon metabolism is a genuinely central part of human biology, and its markers can reveal treatable deficiencies. The error lies in treating a common genetic variant as a diagnosis and in assuming that biochemical plausibility guarantees clinical benefit. Grounded in the evidence, the topic becomes much simpler: find and treat deficiencies, ensure folate before conception, and interpret genetic reports with care.